New treatment for aggressive triple-negative breast cancer using a dual-payload antibody-drug conjugate
Official title: Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
Funded at Ohio State University · NIH-10893502 · Data updated 2026-11-12
This study is testing a new treatment for triple-negative breast cancer that combines chemotherapy and immunotherapy to better target cancer cells and boost the immune system, and it's designed for patients looking for more effective options against this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 25, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $553,091 |
| NIH project number | 5R01CA281980-02 |
| Project ID | NIH-10893502 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded to standard treatments.
✕Less likely to help
Patients with non-triple-negative breast cancers or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for triple-negative breast cancer (TNBC) that combines chemotherapy with immunotherapy. The approach utilizes a dual-payload antibody-drug conjugate designed to target specific cancer cells while enhancing the immune response against the tumor. By using a humanized monoclonal antibody that targets CD276, the treatment aims to overcome resistance to existing therapies and significantly reduce tumor size and metastasis. The research involves preclinical evaluations in animal models to assess the effectiveness of this innovative therapy.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promise in using antibody-drug conjugates and immunotherapy for cancer treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Liu, Xiaoguang Margaret — Ohio State University
- Study coordinator: Liu, Xiaoguang Margaret
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.